Laidlaw analyst Yale Jen initiated coverage of Nuvectis Pharma (NVCT) with a Buy rating and $19 price target Nuvectis is an early to ...
AstraZeneca will buy all outstanding equity of EsoBiotec for on a cash and debt-free basis, which includes an initial payment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results